{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:25:11Z","timestamp":1776749111190,"version":"3.51.2"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.ejphar.2009.02.007","type":"journal-article","created":{"date-parts":[[2009,2,14]],"date-time":"2009-02-14T15:50:05Z","timestamp":1234626605000},"page":"35-40","source":"Crossref","is-referenced-by-count":34,"title":["Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors"],"prefix":"10.1016","volume":"607","author":[{"given":"Yoshihiro","family":"Tadori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2009.02.007_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3565(24)37778-X","article-title":"A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194","volume":"287","author":"Audinot","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2009.02.007_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib3","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which cause 50\/cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2009.02.007_bib4","first-page":"1","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"AiA","author":"Findling","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 4","key":"10.1016\/j.ejphar.2009.02.007_bib5","doi-asserted-by":"crossref","first-page":"S556","DOI":"10.1016\/S0924-977X(08)70847-2","article-title":"Long-term efficacy and safety of aripiprazole in children and adolescents with mania","volume":"18","author":"Forbes","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2009.02.007_bib6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","article-title":"Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study","volume":"165","author":"Grunder","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib7","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2009.02.007_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib11","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania","volume":"160","author":"Keck","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2008.33","article-title":"Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride","author":"Kegeles","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2009.02.007_bib13","series-title":"Pharmacologic Analysis of Drug\u2013Receptor Interaction","author":"Kenakin","year":"1997"},{"key":"10.1016\/j.ejphar.2009.02.007_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","article-title":"The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine","volume":"187","author":"Kern","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2009.02.007_bib15","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/sj.npp.1300836","article-title":"Occupancy of striatal and extrastriatal dopamine D2\/D3 receptors by olanzapine and haloperidol","volume":"30","author":"Kessler","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2009.02.007_bib16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0006-3223(02)01602-5","article-title":"Functional effects of antipsychotic drugs: comparing clozapine with haloperidol","volume":"53","author":"Lahti","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"164","author":"Mamo","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Marcus","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2009.02.007_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2009.02.007_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1523\/JNEUROSCI.03-04-00733.1983","article-title":"Dopamine receptor antagonism by the novel antianxiety drug, buspirone","volume":"3","author":"McMillen","year":"1983","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2009.02.007_bib21","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib22","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v68n1210","article-title":"Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis","volume":"68","author":"Miller","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","article-title":"Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist","volume":"400","author":"Pilla","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2009.02.007_bib25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0197-0186(95)00156-5","article-title":"Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study","volume":"29","author":"Semba","year":"1996","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2009.02.007_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2005.02.051","article-title":"Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic","volume":"515","author":"Tadori","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2009.02.007_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2007.07.031","article-title":"Difference in agonist\/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912","volume":"574","author":"Tadori","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2009.02.007_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2008.09.008","article-title":"Characterization of aripiprazole partial agonist activity at human dopamine D3 receptor","volume":"597","author":"Tadori","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl 51","key":"10.1016\/j.ejphar.2009.02.007_bib30","doi-asserted-by":"crossref","first-page":"s96","DOI":"10.1192\/bjp.191.51.s96","article-title":"Aripiprazole in the treatment of the psychosis prodrome","volume":"191","author":"Woods","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2009.02.007_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s002130000643","article-title":"Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone","volume":"154","author":"Yasuno","year":"2001","journal-title":"Psychopharmacology"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909001460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909001460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T18:30:41Z","timestamp":1738953041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299909001460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":31,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0014299909001460"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2009.02.007","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}